The difference between GMP and GDP is one of the most common sources of confusion for people entering the pharmaceutical industry — and for suppliers and logistics partners too: both acronyms speak of "good practices", both stem from the same European regulatory framework, yet they cover two distinct phases of the medicinal product lifecycle. GMP (Good Manufacturing Practice) governs manufacturing and quality control; GDP (Good Distribution Practice) governs wholesale distribution — everything that happens to the finished product from the moment it leaves the manufacturing site until it reaches pharmacies, hospitals and other distributors. In this article we cover definitions, legal bases, authorisations, responsible roles and the points where the two worlds meet, with a comparison table ready for internal training.
Difference between GMP and GDP: two phases, two rulebooks
The quickest way to pin down the difference between GMP and GDP is to think in lifecycle phases:
- GMP — Good Manufacturing Practice: ensures that medicinal products are manufactured and controlled to the quality standards appropriate to their intended use and to the Marketing Authorisation. It covers production, packaging, quality control and batch release.
- GDP — Good Distribution Practice: ensures that the quality and integrity of medicinal products are maintained throughout the distribution chain, and that products remain within the legal supply chain, keeping falsified medicines out.
In other words: GMP builds product quality, GDP preserves it up to the point of dispensing. A warehouse that stores a perfectly manufactured batch badly undoes the GMP work; that is why the two systems are complementary, not alternatives.
What GMP is and where it is written
In the European Union, GMP for human medicinal products has its legal basis in Directive 2001/83/EC and Commission Directive (EU) 2017/1572, and is detailed in the EudraLex Volume 4 guidelines: Part I for finished medicinal products, Part II for active substances (APIs), Part III for quality-system-related documents, and the Annexes for specific cases (sterile products, computerised systems, qualification and validation, and more).
Anyone manufacturing or importing medicinal products must hold a manufacturing authorisation (Article 40 of Directive 2001/83/EC) and must have a Qualified Person (QP) who certifies each batch before market release. The whole GMP framework revolves around the Pharmaceutical Quality System: production and laboratory controls, validation, deviation and CAPA management, data integrity, batch records and traceability of every operation.
What GDP is and where it is written
GDP for human medicinal products is defined by the Guidelines of 5 November 2013 (2013/C 343/01), adopted by the European Commission on the basis of Articles 84 and 85b of Directive 2001/83/EC. Wholesale distribution is defined by Article 1(17) of the same Directive: procuring, holding, supplying or exporting medicinal products, apart from supplying them to the public.
Anyone performing wholesale distribution must hold a wholesale distribution authorisation (Article 77 of Directive 2001/83/EC) and must designate a Responsible Person (RP), the figure required by Article 79 and by chapter 2.2 of the GDP guidelines, who personally answers for the distribution quality system: supplier and customer qualification, storage and transport conditions, management of returns, complaints, recalls and suspected falsifications. There are also dedicated GDP guidelines for active substances (Guidelines of 19 March 2015, 2015/C 95/01), which apply to API importers and distributors.
Topics like this one — regulations explained in practical terms, without jargon — are the heart of The Pragmatic GMP, GuideGxP's free weekly newsletter: one email a week with GMP and GDP regulatory updates and practical tools for quality professionals. Subscribe here.
GMP vs GDP: comparison table
| Aspect | GMP | GDP |
|---|---|---|
| Phase covered | Production, packaging, quality control, batch release | Procuring, holding, supplying and exporting at wholesale level |
| Main EU reference | EudraLex Volume 4 (Dir. 2001/83/EC, Dir. (EU) 2017/1572) | Guidelines 2013/C 343/01 (Articles 84 and 85b, Dir. 2001/83/EC) |
| Authorisation required | Manufacturing authorisation (Article 40) | Wholesale distribution authorisation (Article 77) |
| Key role | Qualified Person (QP): certifies the release of each batch | Responsible Person (RP): safeguards the distribution quality system |
| Operational focus | Manufacturing processes, validation, quality control, data integrity | Storage, transport, supplier/customer qualification, anti-falsification |
| Core document | Batch record and batch dossier | Purchase/sales records and traceability of movements |
| Inspections | Competent authority over the manufacturing site | Competent authority over the distributor |
Where GMP and GDP meet
In day-to-day practice the boundary line is not a wall, and audits prove it. The three most important touchpoints are:
- The manufacturer distributing its own products. A manufacturing authorisation includes the right to distribute the medicinal products it covers, but for those activities the manufacturer must comply with GDP: the shipping warehouse, transport and customer qualification fall within the distribution perimeter even inside a GMP site.
- Storage and transport conditions. The conditions defined during development and authorisation (label, stability studies) must be maintained in distribution: cold chain, temperature mapping and excursion management are where GMP and GDP speak the same language.
- Recalls and quality defects. An effective recall requires the MA holder, the manufacturer and all distributors to reconstruct quickly where each batch is: GDP traceability is the extension of GMP traceability.
Typical mistakes to avoid
- Thinking GDP concerns "wholesalers only": warehousing providers, brokers (for the specific obligations of Article 85b) and manufacturers shipping their own batches also operate under GDP requirements.
- Applying GMP checklists to a distribution warehouse (or vice versa): the chapters, responsible roles and expected evidence differ; a GDP audit assesses carrier qualification and proof of delivery, not process validation.
- Confusing QP and RP: the QP certifies batches at release, the RP oversees the distribution quality system. They are roles with different legal bases, requirements and responsibilities.
- Forgetting GDP for active substances: API importers and distributors have a dedicated reference (2015/C 95/01), distinct from both GMP Part II and medicinal-product GDP.
GuideGxP recommendation
If you work in QA or supply chain, build an internal matrix mapping each activity (receipt, storage, dispatch, transport, returns) to the applicable reference — EudraLex Volume 4 or 2013/C 343/01 — and to the responsible role. It is the simplest tool to answer the audit question "why is this activity managed this way?" and to avoid grey areas between manufacturing and distribution. Also formalise in quality agreements with warehousing providers and carriers who does what: GDP responsibility cannot be delegated away through a service contract.
To go beyond the regulatory overview: our guide GDP Responsible Person (RP) — Operational Guide to Good Distribution Practice covers the distribution quality system, supplier and customer qualification, transport and the medicinal product supply chain, with a toolkit of ready-to-use Excel and Word templates.